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IMPORTANCE Individually calibrated biomechanical footwear therapy may improve pain and
physical function in people with symptomatic knee osteoarthritis, but the benefits of this
therapy are unclear.
OBJECTIVE To assess the effect of a biomechanical footwear therapy vs control footwear over
24 weeks of follow-up.
DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted at a Swiss university
hospital. Participants (N = 220) with symptomatic, radiologically confirmed knee
osteoarthritis were recruited between April 20, 2015, and January 10, 2017. The last
participant visit occurred on August 15, 2017.
INTERVENTIONS Participants were randomized to biomechanical footwear involving shoes
with individually adjustable external convex pods attached to the outsole (n = 111) or to
control footwear (n = 109) that had visible outsole pods that were not adjustable and did not
create a convex walking surface.
MAIN OUTCOMES AND MEASURES The primary outcome was knee pain at 24 weeks of
follow-up assessed with the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) pain subscore standardized to range from 0 (no symptoms) to 10 (extreme
symptoms). The secondary outcomes included WOMAC physical function and stiffness
subscores and the WOMAC global score, all ranging from 0 (no symptoms) to 10 (extreme
symptoms) at 24 weeks of follow-up, and serious adverse events.
RESULTS Among the 220 randomized participants (mean age, 65.2 years [SD, 9.3 years]; 104
women [47.3%]), 219 received the allocated treatment and 213 (96.8%) completed
follow-up. At 24 weeks of follow-up, the mean standardized WOMAC pain subscore improved
from 4.3 to 1.3 in the biomechanical footwear group and from 4.0 to 2.6 in the control
footwear group (between-group difference in scores at 24 weeks of follow-up, −1.3 [95% CI,
−1.8 to −0.9]; P < .001). The results were consistent for WOMAC physical function subscore
(between-group difference, −1.1 [95% CI, −1.5 to −0.7]), WOMAC stiffness subscore
(between-group difference, −1.4 [95% CI, −1.9 to −0.9]), and WOMAC global score
(between-group difference, −1.2 [95% CI, −1.6 to −0.8]) at 24 weeks of follow-up. Three
serious adverse events occurred in the biomechanical footwear group compared with 9 in the
control footwear group (2.7% vs 8.3%, respectively); none were related to treatment.
CONCLUSIONS AND RELEVANCE Among participants with knee pain from osteoarthritis, use of
biomechanical footwear compared with control footwear resulted in an improvement in pain
at 24 weeks of follow-up that was statistically significant but of uncertain clinical importance.
Further research would be needed to assess long-term efficacy and safety, as well as
replication, before reaching conclusions about the clinical value of this device.
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K nee osteoarthritis affects approximately 265 millionpeople worldwide and was estimated in 2017 toaccount for 8.3 million years lived with disability.1 The
prevalence of knee osteoarthritis is rising due to population
aging and the increasing prevalence of obesity. Acetamino-
phen, nonsteroidal anti-inflammatory drugs, and opioids are
most commonly used to treat the pain associated with
osteoarthritis,2 but have limited effectiveness3,4 and are asso-
ciated with adverse effects.3,5,6 In the US, the rates of knee
replacement surgery, almost all related to osteoarthritis,
have been increasing, in part because of ineffective nonsurgi-
cal treatments.
Biomechanical treatments for knee osteoarthritis have
been developed to reduce pain, improve physical function,
and potentially slow disease progression,7 but evidence
of their effectiveness has been inconclusive.8,9 Two small
prospective, nonrandomized clinical studies suggested that
an individualized biomechanical footwear system may
improve pain and physical function in people with sympto-
matic knee osteoarthritis.10,11 In those studies, the footwear
system consisted of shoes with 2 convex pods on the out-
soles, individually calibrated based on findings from
detailed gait studies. Adjustment of the location of the pods
may alter limb biomechanics and reduce stress on osteoar-
thritic knee compartments.12-14 Walking on the convex pods
results in gait alterations, and these alterations are hypoth-
esized to induce reconditioning of the neuromuscular sys-
tem and improve pathological gait patterns.15
The objective of this study, the Biomechanical Therapy for
Osteoarthritis of the Knee (BIOTOK) randomized clinical trial,
was to determine whether the use of biomechanical footwear
was more effective than the use of control footwear for im-
proving knee pain in participants with knee osteoarthritis.
Methods
Study Design and Participants
The trial protocol and statistical analysis plan appear in
Supplement 1 and Supplement 2, respectively. This was an in-
vestigator-initiated single-center randomized clinical trial con-
ducted among participants with symptomatic knee osteoar-
thritis, which compared a biomechanical footwear therapy using
shoes with 2 individually calibrated convex pods on the out-
soles (AposTherapy, Apos Medical Assets; eFigures 1 and 2 in
Supplement 3) with a similarly appearing control footwear.
We enrolled men and nonpregnant women aged 40 years
or older who had symptomatic, radiologically confirmed knee
osteoarthritis according to criteria from the American Col-
lege of Rheumatology.16 At the screening visit, participants had
knee pain lasting 6 months or longer and a score of 3 or greater
on the Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC) pain subscale17 (standardized to range
from 0-10). The full eligibility criteria and description for the
selection of the index knee appear in Supplement 3.
Individuals were excluded if they had a history of inflam-
matory rheumatic disease, had undergone knee surgery dur-
ing the prior 6 months, had a planned hip or knee surgery
within 24 weeks of the baseline assessment, had received glu-
cocorticoid knee injections within the prior 3 months, or had
a high risk for falls.
The trial was approved by the independent research eth-
ics committee of Canton Bern (KEK-BE 041/215). All partici-
pants provided written informed consent.
Randomization and Blinding
Participants were randomized 1:1 to the biomechanical foot-
wear group or to the control footwear group using a con-
cealed and secure web-based system (Figure 1). Randomiza-
tion was computer-generated using varied block sizes of 2
and 4 and stratified by unilateral vs bilateral knee disease and
predominantly affected compartment (medial vs lateral) in
the index knee.
The biomechanical footwear device consisted of 2 shoes
with 2 convex adjustable rubber pods screwed to the outsole
at the heel and forefoot (eFigures 1 and 2 in Supplement 3). The
control footwear was specifically designed by the manufac-
turer for this trial to have a similar appearance to the biome-
chanical footwear, but with pods embedded in the transpar-
ent outsole so that they were visible yet did not create a convex
walking surface (eFigure 3 in Supplement 3).
To try to maintain blinding of the participants, they were
kept unaware of the study design and the use of the control
footwear. Participants were informed in a neutral manner that
2 different types of footwear were being compared (Supple-
ment 3). Both the biomechanical and control footwear were
presented on the manufacturer’s website, and the control foot-
wear was described as a device with a novel design of the sole
(eFigure 3 in Supplement 3).
The technicians and study nurses who coordinated the
clinical visits could not be blinded to treatment group but were
asked not to disclose the treatment or the nature of the con-
trol footwear study component to participants. The techni-
cians were from Israel and did not speak German, therefore,
direct interaction between the technicians and participants was
limited. Verbal communication was carried out through the
Key Points
Question Is an individualized biomechanical footwear therapy
effective for reducing knee pain in people with knee
osteoarthritis?
Findings In this randomized clinical trial that included 220
participants with knee pain due to knee osteoarthritis, treatment
with an individualized biomechanical footwear therapy compared
with control footwear resulted in a lower Western Ontario and
McMaster Universities Osteoarthritis Index pain subscore (range,
0-10) after 24 weeks of follow-up (1.3 vs 2.6, respectively), a
difference that was statistically significant.
Meaning Although use of biomechanical footwear compared with
control footwear resulted in an improvement in knee pain at 24
weeks of follow-up that was statistically significant, the difference
was of uncertain clinical importance, and further research is
needed to assess long-term efficacy and safety.
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translating study nurses, who were independent of the manu-
facturer and were encouraged to facilitate unbiased partici-
pant interaction. The remaining study personnel (perform-
ing data entry, management, and data cleaning) and the
statistician were blinded to the intervention until all primary
and secondary analyses were completed.
The consent form did not state that the control footwear
was intended to be ineffective; rather, it implied that both types
of shoes may be effective. Furthermore, the manufacturer’s
website was altered to imply potentially therapeutic benefits
of both the intervention and the control footwear. Therefore,
the trial could be considered potentially deceptive according
to international guidelines.18
Both the biomechanical and control footwear included
some therapeutic elements. Both were high-top shoes, which
provided more stability and proprioceptive input than loose
shoes or sandals. Furthermore, proposed mechanisms of the
biomechanical footwear were hypothetical at the initiation of
this trial, and the trial was considered to entail no more than
minimal risk and burden to participants according to Article 2
of the Swiss clinical trials ordinance.19
Therefore, the responsible research ethics committee did
not classify the trial as involving incomplete participant in-
formation (ie, did not consider the study procedures to be de-
ceptive) according to Article 18 of the Swiss human research
act.20 Nonetheless, because the trial may have been consid-
ered deceptive by some individuals, participants were de-
briefed after the trial was completed.
Participants were advised of the rationale of the placebo-
controlled design, informed of differences between the bio-
mechanical footwear and the control footwear, and informed
about their group allocation, and were given the opportunity
to withdraw consent to participate. The criteria specified in
the international guidelines18 for trials that withhold infor-
mation or use deception with respect to this trial appear in
Supplement 3.
Figure 1. Participant Recruitment, Randomization, and Follow-up
697 Patients assessed for eligibility
477 Excluded
455 Ineligible
22 Did not provide consent (lost interest in participating)
274 Had WOMAC pain score <3a
71 Prior knee replacement
32 Prior osteotomy
15 History of inflammatory rheumatic disease
10 Planned hip or knee surgery within 24 wk
8 Had Kellgren-Lawrence grade <2b
5 Unable to travel to treatment center
5 History of knee pain <6 mo
4 Aged <40 y
3 At high risk for falling (STEADI score >4)c
3 Had fibromyalgia
25 Other reasons
220 Randomized
109 Included in primary analysis
104 Had data for primary outcome
5 Did not have data for primary outcome
4 Refused to participate in follow-up
1 Lost to follow-up
1 No symptom improvement
1 Symptoms worsened
1 Underwent total knee replacement
1 Other reason (unwilling)
109 Had data for primary outcome
2 Did not have data for primary outcome
2 Refused to participate in follow-up
(unwilling)
109 Randomized to wear control footwear
109 Received intervention as randomized
111 Randomized to wear biomechanical
footwear
110 Received intervention as randomized
1 Did not receive intervention as
randomized (refused treatment)
111 Included in primary analysis
13 Discontinued treatmentd
5 No symptom improvement
3 Symptoms worsened
2 Underwent total knee replacement
1 Underwent total hip replacement
1 Lost to follow-up
1 Other reason (unwilling)
7 Discontinued treatmentd
2 No symptom improvement
2 Symptoms worsened
1 Adverse event
2 Other reason (unwilling)
a The Western Ontario and McMaster
Universities Osteoarthritis Index
(WOMAC) is a self-administered
questionnaire with a score range
from 0 to 10 (0, no symptoms;
10, extreme symptoms).
b The Kellgren-Lawrence grade
ranges from 0 to 4; a grade of 2 or
greater indicates definite
osteoarthritis on anteroposterior
weight-bearing radiograph.
c STEADI indicates Stopping Elderly
Accidents, Deaths, and Injuries;
a score greater than 4 at the
screening visit was considered to
indicate a high risk of falls. The score
range is 0 to 14.
d Of the 7 participants in the
biomedical footwear group and 13
participants in the control footwear
group who discontinued treatment,
2 and 5, respectively, did not have
data for the primary outcome and
were counted as part of those who
discontinued treatment. Multiple
imputation was used for missing
outcome data.
Research Original Investigation Effect of Biomechanical Footwear on Knee Pain in People With Knee Osteoarthritis
1804 JAMA May 12, 2020 Volume 323, Number 18 (Reprinted) jama.com
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a E-Library Insel User  on 05/14/2020
Procedures
Participants in both groups underwent an initial fitting of
their assigned footwear by technicians at baseline and during
recalibration at 4, 8, 12, and 16 weeks of follow-up. The posi-
tioning of the external pods was individually adjusted on the
biomechanical footwear, in accordance with gait patterns and
reported pain intensity during walking, with the aim of
decreasing clinically observed malalignment and reported
pain intensity, and increasing gait symmetry13,14,21,22 as
determined by 2-dimensional computerized spatiotemporal
gait analysis software (Zeno walkway version Z-216T and
PKMAS version 5.07C3, both manufactured by ProtoKinetics;
Supplement 3). Participants in the control footwear group
received a simulated calibration that mimicked calibration of
the biomechanical footwear. The technicians provided by the
manufacturer performed all device-related procedures (gait
analyses, fitting, and calibrations of the biomechanical and
control footwear).
Participants were instructed to use the footwear during in-
door activities for a half hour each day during the first week
of the intervention, with subsequent increases of 10 minutes
per week on average but were not given explicit instructions
to perform specific home-based exercises. After 6 weeks of
follow-up, the participants were advised to use the footwear
to walk outdoors. The participants were asked to discontinue
their regular pain medication and advised that other interven-
tions, such as physical therapy, should be avoided during the
trial. They were permitted daily therapy as needed with acet-
aminophen at a maximum dose of 2 g and the amounts taken
were recorded at each visit.
Outcomes
The prespecified primary outcome was pain at the end of treat-
ment (24-week follow-up) in the index knee assessed with the
WOMAC pain subscore (visual analog version) (standardized
range, 0-10; 0 = no symptoms and 10 = extreme symptoms).17
The secondary outcomes prespecified in the protocol
were WOMAC global score and WOMAC physical function
and stiffness subscores (all 3 with standardized range, 0-10;
0 = no symptoms) at 12 and 24 weeks of follow-up; WOMAC
pain subscore at 4, 8, 12, and 16 weeks of follow-up; the
physical and mental component summary scores of the
Medical Outcomes Study 36-item Short Form Health Survey
(SF-36) (standardized to have a mean of 50 [SD, 10] for the
general population; theoretical range, 0-100; 100 = best)23 at
12 and 24 weeks of follow-up; gait velocity, step length, and
single limb support measured by 2-dimensional computer-
ized gait analysis when walking barefoot at 4, 8, 12, 16, and
24 weeks of follow-up; self-reported time spent wearing the
footwear per day; self-reported health care use; and self-
reported analgesic use (because between-group differences
in analgesic use could result in performance bias).24 The
minimal clinically important differences were not considered
when planning the trial.
Other prespecified outcomes were treatment response
defined as decreases of 30% and 50% in WOMAC pain sub-
score from baseline.25 A treatment response defined as a
50% decrease in WOMAC pain subscore from baseline was
not prespecified in the protocol (Supplement 1), but was
included in the statistical analysis plan (Supplement 2).
The adverse events prespecified in the protocol were
falls, any adverse events, serious adverse events, dropped
out for any reason, and dropped out due to adverse events
(Supplement 1). The WOMAC scores,17 analgesic intake, and
gait analysis parameters were recorded at baseline and at 4,
8, 12, 16, and 24 weeks of follow-up; and the SF-36 scores and
health care use were recorded at baseline and at 12 and 24
weeks of follow-up. The adverse events and the time spent
wearing the footwear were recorded at each follow-up visit.
Two investigators (S.R. and P.J.) blinded to the assigned treat-
ment adjudicated all potential adverse events based on notes
by participants and nurses, and, in cases of potential serious
adverse events, based on relevant medical records.
Statistical Analysis
A sample size of 100 participants per group yielded
80% power to detect a between-group difference of 1.05
on a standardized WOMAC pain scale ranging from 0 to
10 at a 2-sided α level of .05. This between-group differ-
ence corresponds to a moderate effect size of 0.4-SD units,
assuming a typical SD of 2.65.4 The protocol prespecified
the use of analyses of covariance for all continuous out-
comes, adjusted for the outcome’s baseline values. For this
approach, a sample size of 100 participants per group would
yield approximately 90% power, assuming a correlation of
0.5 between baseline and 24 weeks of follow-up. Anticipat-
ing an attrition rate of 10%, the target sample size was
220 participants.
Continuous outcomes were analyzed using analysis of
covariance adjusted for the outcome’s baseline values and
variables used for stratified randomization, considering
only the assessments of the index knee for each participant.
Binary outcomes were analyzed using Cochran-Mantel-
Haenszel tests stratified by stratification variables.26 Partici-
pants were included in the analyses according to their ran-
domized allocation,27 using multiple imputation for missing
outcome data, using all baseline characteristics (age,
sex, body mass index, blood pressure, medical history,
WOMAC scores, SF-36 scores, and parameters of gait analy-
sis), outcomes at all time points, the treatment indicator,
and stratification variables to generate 20 imputed data sets
(Supplement 2 and Supplement 3).
Prespecified subgroup analyses of the primary out-
come were performed according to the predominantly
affected compartment and the presence or absence of
symptomatic contralateral knee osteoarthritis and were
accompanied by tests for interaction. A post hoc subgroup
analysis was performed according to WOMAC pain intensity
at baseline.28 Prespecified sensitivity analyses of the pri-
mary outcome included a per-protocol analysis, a complete
case analysis, adjustments for potential procedural con-
founders, and a linear mixed-effects model to analyze all
knees (ie, index or both index and contralateral knee) with a
baseline WOMAC pain subscale score of 3 or greater. Post
hoc sensitivity analyses of WOMAC scores, SF-36 scores,
and parameters of gait analyses were performed using all
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time points in a linear mixed-effects regression model
(Supplement 2 and Supplement 3).
The P values and 95% CIs were 2-sided and P values ≤.05
were considered statistically significant. Because of the po-
tential for type I error due to multiple comparisons, the find-
ings for the analyses of the secondary outcomes should be in-
terpreted as exploratory. All analyses were performed using
R version 3.3.2 (R Foundation for Statistical Computing)29 by
an independent statistician located within an academic clini-
cal trials unit (in Bern, Switzerland) who was unaware of group
assignment. The statistical analysis plan was finalized after
completion of follow-up, but before examination of the data.
Data were interpreted and conclusions formulated prior to the
unblinding of the investigators.
Results
Between April 20, 2015, and January 10, 2017, 220 partici-
pants were randomized. There were 111 participants random-
ized to the biomechanical footwear group and 109 partici-
pants randomized to the control footwear group (Figure 1). One
participant in the biomechanical footwear group refused treat-
ment and did not receive the intervention. Seven partici-
pants in the biomechanical footwear group and 13 partici-
pants in the control footwear group discontinued treatment
during follow-up. The last participant visit occurred on August
15, 2017. There were complete data for the primary outcome
at 24 weeks of follow-up for 109 participants (98.2%) in the
biomechanical footwear group and 104 participants (95.4%)
in the control footwear group.
After trial completion, 217 of the 220 randomized partici-
pants were reached and advised of the potential for decep-
tion in the study design. Of the 3 participants who were not
reached (all in the biomechanical footwear group), 1 had died
and 2 were lost to follow-up. None of the remaining 217 par-
ticipants withdrew consent after learning that the trial
involved randomization to either the biomechanical foot-
wear group or the control footwear group that was expected
to be ineffective.
Baseline characteristics were similar between the partici-
pants randomized to each group (Table 1 and eTable 1 in
Supplement 3). The study population had a mean age of 65.2
years (SD, 9.3 years), 104 were women (47.3%), and the popu-
lation had a mean body mass index (calculated as weight in
kilograms divided by height in meters squared) of 28.0 (SD,
4.6). Medial knee osteoarthritis was present in 90.9% of par-
ticipants and unilateral disease in 67.7%. The number of par-
ticipants with missing data was between 0 and 3 (1.4%) for
baseline characteristics (eTable 2 in Supplement 3) and
between 2 (0.9%) and 29 (13.2%) for outcomes (eTable 3 in
Supplement 3).
Primary Outcome
The biomechanical footwear group had a larger decrease in
standardized WOMAC pain subscore at 24 weeks of follow-up
than the control footwear group (mean score, 1.3 vs 2.6,
respectively; between-group difference, −1.3 [95% CI, −1.8 to
−0.9]; P < .001) (Figure 2 and Table 2).
Secondary Outcomes
The biomechanical footwear group had larger declines in the
secondary outcomes of WOMAC physical function and stiff-
ness subscores and WOMAC global score at 24 weeks of
follow-up (Figure 2 and Table 2). Between-group differences
in velocity, step length, and single limb support emerged in
favor of the biomechanical footwear group between 12 and
24 weeks of follow-up (Table 2). The mean self-reported time
Table 1. Participant Characteristics at Baseline
Characteristic
Biomechanical
Footwear
(n = 111)
Control
Footwear
(n = 109)
Sex, No. (%)
Female 51 (45.9) 53 (48.6)
Male 60 (54.1) 56 (51.4)
Age, mean (SD), y 65.3 (9.2) 65.0 (9.3)
Weight, mean (SD), kg 80.6 (15.7) 82.7 (14.2)
Height, mean (SD), cm 170.4 (8.6) 170.9 (8.2)
Body mass index, mean (SD)a 27.7 (4.8) 28.3 (4.3)
Knee-related characteristicsb
History of meniscal resection 55 (49.5) 50 (45.9)
Knee joint effusion 18 (16.2) 17 (15.6)
Kellgren-Lawrence gradec
2 33 (29.7) 36 (33.0)
3 50 (45.0) 46 (42.2)
4 28 (25.2) 27 (24.8)
Medial knee osteoarthritis 101 (91.0) 99 (90.8)
WOMAC score, mean (SD)d
Pain 4.3 (1.8) 4.0 (2.0)
Physical function 3.5 (1.8) 3.4 (1.8)
Stiffness 5.0 (2.4) 4.4 (2.4)
Global 3.8 (1.7) 3.6 (1.7)
SF-36 score, mean (SD)e
Physical component 40.4 (7.1) 40.3 (6.2)
Mental component 57.0 (7.4) 56.4 (8.8)
Analgesic use during past week,
No. (%)
44 (39.6) 35 (32.1)
Abbreviations: SF-36, 36-item Short Form Health Survey; WOMAC, Western
Ontario and McMaster Universities Osteoarthritis Index.
a Calculated as weight in kilograms divided by height in meters squared.
b These characteristics are in regard to the index knee and are expressed as No.
(%) unless otherwise indicated. The percentages may not total 100 because of
rounding. Additional baseline characteristics appear in eTable 1 in
Supplement 3.
c Ranges from 0 to 4. A grade of 2 or greater indicates definite osteoarthritis on
anteroposterior weight-bearing radiograph. A grade of 2 indicates definite
osteophytes and possible joint space narrowing; grade 3, multiple
osteophytes, definite joint space narrowing, sclerosis, and possible bony
deformity; and grade 4, large osteophytes, marked definite joint space
narrowing, severe sclerosis, and definite bony deformity.
d A self-administered questionnaire including 5 questions on pain, 17 questions
on physical function, and 2 questions on stiffness. All 4 composite scores were
standardized to range from 0 to 10 (0, no symptoms; 10, extreme symptoms).
For the WOMAC pain subscore, a score of 4 or less indicates mild pain; a score
of 5 to 7, moderate pain; and a score greater than 7, severe pain.28
e Each component score has a mean of 50 (SD, 10) for the general population.
Higher summary scores indicate better health.
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Figure 2. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Scores During 24 Weeks
of Follow-up
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The box represents the median and
interquartile range, the whiskers
represent the most extreme values
within 1.5 times of the interquartile
range beyond the 25th and 75th
percentile, and the circles represent
the more extreme values. The
WOMAC is a self-administered
questionnaire including 5 questions
on pain, 17 questions on physical
function, and 2 questions on
stiffness. All 4 composite scores were
standardized to range from 0 to 10
(0, no symptoms; 10, extreme
symptoms).
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spent wearing the footwear at 24 weeks of follow-up was
209 minutes/day in the biomechanical footwear group vs 174
minutes/day in the control footwear group (between-group
difference, 35 minutes/day [95% CI, 4-67 minutes/day]).
For the SF-36 physical component summary score, there
was no statistically significant between-group difference for
the biomechanical footwear group vs the control footwear
group (mean score, 45.9 vs 44.5, respectively; between-
group difference 1.4 [95% CI, −0.5 to 3.2]). There were no sig-
nificant between-group differences in the SF-36 mental com-
ponent summary score, for analgesic use, or for health care use.
Additional prespecified secondary outcomes, including types
of analgesics, types of clinicians visited, use of corticosteroid
injections, and performed or planned knee replacement sur-
geries appear in eTable 4 in Supplement 3.
The other prespecified outcomes appear in eTable 5 in
Supplement 3, including participants with a treatment
response achieving a 30% or 50% reduction for the WOMAC
pain subscore from baseline to 24 weeks of follow-up. Among
participants in the biomechanical footwear group, 92%
achieved a 30% reduction for the WOMAC pain subscore vs
58% in the control footwear group (risk difference, 34% [95%
CI, 23%-45%]), and 83% vs 42%, respectively, achieved a
50% reduction for the WOMAC pain subscore (risk differ-
ence, 41% [95% CI, 28%-52%]); the corresponding numbers
needed to treat were 3 (95% CI, 2-5) and 3 (95% CI, 1-4).
The prespecified subgroup analyses of the primary out-
come according to the predominantly affected compartment
and symptomatic contralateral disease did not show signifi-
cant treatment × subgroup interactions (eTable 6 in Supple-
ment 3). The sensitivity analyses of the primary outcome, in-
cluding a per-protocol analysis, a complete case analysis,
adjustments for potential procedural confounders, and a lin-
ear mixed-effects model to analyze all knees with a baseline
WOMAC pain subscore of 3 or greater were consistent with the
primary outcome analysis (eTables 7-11 in Supplement 3).
Adverse Events
Twenty-six participants (23.4%) in the biomechanical foot-
wear group and 38 participants (34.9%) in the control foot-
wear group experienced an adverse event and 3 (2.7%) and 9
(8.3%), respectively, experienced serious adverse events
(Table 3). None were considered to be related to treatment.
Of the serious adverse events, there were 0 in the biome-
chanical footwear group vs 4 in the control footwear group
that were musculoskeletal, 1 vs 3, respectively, that were cir-
culatory, and 2 vs 2 that were in other categories (eTable 12 in
Supplement 3). One or more falls occurred in 2 participants
(1.8%) in the biomechanical footwear group and in 4 partici-
pants (3.7%) in the control footwear group. One participant in
the control group fell while wearing the control footwear.
Post Hoc Analyses
A post hoc subgroup analysis of the primary outcome by
WOMAC pain intensity at baseline did not show significant
treatment × subgroup interactions (eTable 6 in Supple-
ment 3). The post hoc use of a mixed-effects model simulta-
neously including all time points showed results similar to
those of the main analyses. In the mixed-effects models, there
were significant between-group differences in the WOMAC pain
and physical function subscores and in the WOMAC global score
at 12, 16, and 24 weeks of follow-up, and in the WOMAC stiff-
ness subscore at 16 and 24 weeks of follow-up. Significant be-
tween-group differences in parameters of gait analysis were
observed for velocity and step length at 12, 16, and 24 weeks
of follow-up and for single limb support at 24 weeks of
follow-up (eTable 13 in Supplement 3).
Table 3. Adverse Eventsa
No. (%)
Biomechanical
Footwear
(n = 111)
Control
Footwear
(n = 109)
Any adverse events 26 (23.4) 38 (34.9)
Minor adverse events 23 (20.7) 30 (27.5)
Musculoskeletal 15 (13.5) 21 (19.3)
Knee pain or swellingb 2 (1.8) 3 (2.8)
Low back pain 5 (4.5) 5 (4.5)
Hip pain 5 (4.5) 3 (2.8)
Foot pain 2 (1.8) 3 (2.8)
Other 3 (2.7) 8 (7.3)
Injury 6 (5.4) 9 (8.3)
Ankle sprain 2 (1.8) 1 (0.9)
Fallc 2 (1.8) 4 (3.7)
Other 2 (1.8) 4 (3.7)
Genitourinary 2 (1.8) 2 (1.8)
Circulatory 1 (0.9) 1 (0.9)
Nervous system 0 2 (1.8)
Eye 0 1 (0.9)
Respiratory system 1 (0.9) 0
Digestive system 1 (0.9) 0
Serious adverse eventsd 3 (2.7) 9 (8.3)
Musculoskeletal 0 4 (3.7)
Total hip or knee replacement
surgery
0 3 (2.8)
Low back paine 0 1 (0.9)
Circulatory 1 (0.9) 3 (2.8)
Coronary heart diseasef 1 (0.9) 2 (1.8)
Other 0 1 (0.9)
Genitourinary 1 (0.9) 0
Eye 0 1 (0.9)
Digestive system 1 (0.9) 1 (0.9)
a Adverse event categories correspond to chapters in the International
Statistical Classification of Diseases and Related Health Problems, Tenth
Revision, and are summarized as clinical subcategories if at least 3 participants
experienced a specific type of event.
b Corresponds to local adverse events as prespecified in the protocol.
c Prespecified in the statistical analysis plan. One participant in the control
footwear group experienced a fall while wearing the study footwear.
d Defined as events resulting in hospitalization, prolongation of hospitalization,
persistent or significant disability, congenital abnormality or birth defects of
offspring, life-threatening events, or death.
e One participant in the control footwear group underwent lumbar disc
herniation surgery.
f One participant in the biomechanical footwear group had an acute myocardial
infarction.
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eFigure 4 in Supplement 3 contrasts WOMAC pain sub-
score with the time spent wearing the footwear over the
duration of the trial. The maximal between-group difference
in time spent wearing the footwear occurred at 16 weeks of
follow-up, whereas the maximum between-group difference
in the WOMAC pain subscore was observed 8 weeks later at
24 weeks of follow-up.
Discussion
In this randomized clinical trial, the biomechanical footwear sys-
tem with individually calibrated outsole convex pods was sig-
nificantly more effective than the control footwear at reducing
pain at 24 weeks of follow-up in participants with knee pain from
symptomatic knee osteoarthritis. The results were consistent
for the secondary outcomes of WOMAC physical function and
stiffness subscores and the WOMAC global score at 24 weeks
of follow-up. There were no significant between-group differ-
ences in the physical and mental components of the SF-36.
There are 2 differences between the biomechanical foot-
wear system tested in this trial and other biomechanical
devices such as shoes9 or wedges.8 First, in this trial, the
individualized calibration of proximal and distal pods of the
biomechanical device in the coronal and sagittal planes shifts
the trajectory of the foot’s center of pressure, thereby specifi-
cally changing the direction of the ground reaction force vec-
tor as appropriate for each individual.12,13,30 Second, the con-
vexity of the pods in the biomechanical footwear results in
repetitive gait perturbation, with mild destabilization of the
knee during walking, which in turn may elicit neuromuscular
responses.
To our knowledge, no other published randomized clini-
cal trials have investigated the effectiveness of this biome-
chanical footwear system in people with symptomatic knee os-
teoarthritis. Of 6 published clinical studies,10,11,15,31-33 4 were
uncontrolled studies conducted by the manufacturer,15,31-33
the remaining 2 were prospective and controlled, but not
randomized.10,11 The most rigorous investigation was a pro-
spective nonrandomized controlled study among 57 partici-
pants with symptomatic knee osteoarthritis,10 which found im-
proved pain and physical function with the biomechanical
footwear system compared with the control footwear. How-
ever, the between-group difference in the WOMAC pain sub-
score at 8 weeks of follow-up was not consistent with the nega-
tive 8-week result in the current study. The reason for this
between-group difference is unclear but may be due to lack of
randomization in the prior trial.10
Limitations
This study has several limitations. First, there were differ-
ences in the appearance of the biomechanical footwear and
the control footwear. To overcome this limitation and mini-
mize the likelihood that participants would correctly guess
that they were not receiving the active intervention, partici-
pants were kept unaware that the control footwear was not
expected to have therapeutic benefits. Participants were
informed in a neutral fashion that 2 different types of foot-
wear were being compared. The manufacturer’s website
described the control footwear as a device with a novel
design of the sole, and the participants randomized to the
control group received a simulated calibration that mim-
icked the actual calibration.
Second, the use of a blinding index34 to determine the suc-
cess of blinding was not performed because such an index as-
sumes indistinguishable interventions. Third, the self-
reported time per day wearing the footwear was longer in the
biomechanical footwear group than in the control footwear
group. It is possible that the greater benefit in the biomechani-
cal footwear group was due to longer wear time.
Fourth, analgesic treatment for pain was allowed during
the trial; however, the rates of analgesic use did not differ
between groups. Fifth, it was not possible to explore
changes in knee adduction moments using 3-dimensional
gait analyses.
Sixth, the trial was conducted at a single center, poten-
tially limiting generalizability. Seventh, the between-group
differences occurred only late during follow-up and were
smaller than the observed within-group change from base-
line in the control group. Therefore, the clinical importance
of these findings remains uncertain. Eighth, the findings
from this trial are not generalizable to people at high risk for
falls because these individuals were not eligible to partici-
pate. Ninth, the findings are not generalizable to people
with severe knee pain because these individuals were
underrepresented in the trial.
Conclusions
Among participants with knee pain from osteoarthritis, use
of biomechanical footwear compared with control footwear
resulted in an improvement in pain at 24 weeks of follow-up
that was statistically significant but of uncertain clinical
importance. Further research would be needed to assess
long-term efficacy and safety, as well as replication, before
reaching conclusions about the clinical value of this device.
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